Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) FCF Margin (2020 - 2025)

Historic FCF Margin for Relay Therapeutics (RLAY) over the last 6 years, with Q2 2025 value amounting to 8166.47%.

  • Relay Therapeutics' FCF Margin changed N/A to 8166.47% in Q2 2025 from the same period last year, while for Sep 2025 it was 2978.3%, marking a year-over-year decrease of 1543700.0%. This contributed to the annual value of 2509.49% for FY2024, which is 13177500.0% down from last year.
  • As of Q2 2025, Relay Therapeutics' FCF Margin stood at 8166.47%.
  • In the past 5 years, Relay Therapeutics' FCF Margin registered a high of 8930600.0% during Q4 2023, and its lowest value of 58910.92% during Q2 2023.
  • In the last 5 years, Relay Therapeutics' FCF Margin had a median value of 8166.47% in 2025 and averaged 583026.32%.
  • Per our database at Business Quant, Relay Therapeutics' FCF Margin crashed by 2000000000bps in 2021 and then skyrocketed by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows Relay Therapeutics' FCF Margin stood at 7158.2% in 2021, then crashed by -228bps to 23476.28% in 2022, then soared by 38141bps to 8930600.0% in 2023, then tumbled by -100bps to 520.67% in 2024, then tumbled by -1468bps to 8166.47% in 2025.
  • Its FCF Margin was 8166.47% in Q2 2025, compared to 958.38% in Q1 2025 and 520.67% in Q1 2024.